KANSAS CITY, Kan., May 20, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (CING) (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...
KANSAS CITY - Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company, announced it has been granted a European patent for CTx-1301, its lead drug candidate for Attention Deficit Hyperactivity ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する
フィードバック